Repatha for FH: Evidence Summary, Off-Label Status, and Clinical Use

Evolocumab is the generic name for the brand-name drug Repatha, a fully human monoclonal antibody in the PCSK9-inhibitor class, given by subcutaneous injection. It is not the same molecule as alirocumab (Praluent), another PCSK9 antibody, or inclisiran (Leqvio), a small interfering RNA that works on the same pathway by a different mechanism. This page covers evolocumab specifically for familial hypercholesterolemia (FH), not its general atherosclerotic cardiovascular disease indication.

Evolocumab (Repatha) is FDA-approved for heterozygous familial hypercholesterolemia (HeFH) in adults and in patients aged 10 and older, and for homozygous familial hypercholesterolemia (HoFH) in adults, as an add-on to diet and maximally tolerated statin therapy. Use in children younger than 10, or in patients whose FH is driven by genetic variants outside the LDL-receptor pathway (for example APOB or gain-of-function PCSK9 mutations) that were not the enrollment criteria in the pivotal trials, is off-label. The core clinical tension is that evolocumab's benefit tracks how much functional LDL receptor a patient has left, substantial in HeFH, limited in receptor-negative HoFH, so the same drug produces meaningfully different results depending on genotype, not just diagnosis label.

What is actually FDA-approved for FH, and where does the label stop?

Evolocumab's label is unusual among lipid-lowering drugs because it names familial hypercholesterolemia explicitly rather than relying on a general cardiovascular-risk indication. According to the FDA-approved prescribing information for Repatha, the drug is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH, adults with HoFH, and adults with established atherosclerotic cardiovascular disease. The pediatric HeFH indication covers patients aged 10 and older. Readers should confirm the current label text and any updates directly on the FDA page, since drug labels are revised over time and this summary reflects the version available as of the last review date above.

The approved adult dosing per that label is 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly for HeFH, and 420 mg once monthly for HoFH. For pediatric HeFH patients aged 10 and older, the approved dose is 420 mg once monthly.

Outside that label, the most clinically important off-label populations are:

• Children younger than 10 with genetically confirmed HeFH or HoFH, particularly those with very high LDL-C who cannot wait years for on-label eligibility.
• Patients whose FH phenotype is driven by pathogenic variants in APOB or by PCSK9 gain-of-function mutations rather than classic LDL-receptor (LDLR) mutations, since the pivotal trials enrolled patients mainly by clinical diagnostic criteria (such as Dutch Lipid Clinic Network score) rather than mandatory genetic sequencing of a specific gene.
• Use as a formal add-on to lipoprotein apheresis in refractory HoFH, which is a common real-world practice but is not a labeled combination regimen.

Why does the same drug work less well in homozygous FH?

Evolocumab blocks PCSK9, a circulating protein that normally targets LDL receptors on liver cells for degradation. By blocking PCSK9, evolocumab lets more LDL receptors recycle to the cell surface, which increases clearance of LDL particles from blood.

This mechanism depends on having functional LDL receptors to protect. Patients with HeFH carry one mutated LDLR allele and one working allele, so meaningful receptor capacity remains for evolocumab to amplify. Patients with HoFH carry two mutated alleles; if both are "null" (produce no functional receptor at all), there is little for the drug to act on, and the LDL-C response is small. Patients with at least one "defective" (partially functional) rather than fully null allele tend to respond better than patients with two null alleles. This receptor-genotype gradient, rather than the HeFH/HoFH label alone, is the more precise predictor of response, and it is the reason average trial results in HoFH understate the range of outcomes seen in individual patients.

What do the pivotal trials actually show?

Several named phase 3 randomized trials underlie the FH indication: RUTHERFORD-2 and LAPLACE-2 in heterozygous FH populations, TESLA Part B in homozygous FH, HAUSER-RCT in adolescents aged 10 to 17 with HeFH, and FOURIER as the large cardiovascular outcomes trial in a broader atherosclerotic cardiovascular disease population that included a small FH subgroup. In general terms, published reports describe LDL-C reductions in the range of roughly 55 to 60 percent versus placebo in HeFH trials, roughly 30 percent versus placebo in the HoFH trial, and a similar magnitude of reduction (high 30s percent) in the adolescent HeFH trial. FOURIER reported a reduced rate of major cardiovascular events (a composite of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, and coronary revascularization) with evolocumab versus placebo over roughly two years of follow-up in its overall population; the FH subgroup within FOURIER was directionally consistent but too small to serve as independent proof of cardiovascular benefit specifically in FH.

A note on precision: several specific citation identifiers in earlier drafts of this material could not be independently verified against the correct source paper. The trial names above are genuine, well-known studies in the FH literature, but exact percentage figures, confidence intervals, and subgroup statistics should be checked against the primary publications (search each trial name at pubmed.ncbi.nlm.nih.gov or clinicaltrials.gov) before this article is finalized for publication, rather than treated as confirmed by this draft.

Should evolocumab be used off-label in children under 10 with HoFH?

This is a genuine clinical decision point, not just a labeling technicality. HoFH can produce LDL-C in the hundreds of mg/dL from early childhood, and untreated disease leads to xanthomas and premature coronary disease. No randomized trial has enrolled children younger than 10 for evolocumab, so decisions in this age group rely on case reports, extrapolation from the age-10-and-older pediatric trial, and specialist judgment rather than a dedicated evidence base. Families and clinicians considering this off-label path should understand that:

• Safety data below age 10 is limited to small case series and clinical experience, not randomized comparison.
• Insurance denial is common for off-label pediatric use, and appeals typically require documented genetic testing and specialist attestation.
• Alternatives such as lipoprotein apheresis, ezetimibe, and in some HoFH cases lomitapide have more established (though still limited) pediatric track records and different risk profiles, and should be discussed as comparators, not just as fallback options.

Should evolocumab be used for APOB or PCSK9-variant FH rather than LDLR-driven FH?

Roughly 1 to 2 percent of clinically diagnosed FH is attributable to APOB variants rather than LDLR mutations, with a smaller share due to PCSK9 gain-of-function mutations. Because APOB-FH involves a structurally normal but dysfunctional receptor-binding region on LDL particles rather than a broken receptor, there is a mechanistic argument that evolocumab should work similarly to LDLR-HeFH in this group. However, the pivotal trials did not require genetic confirmation of variant type for most enrollees, so genotype-specific response data for APOB or PCSK9-variant FH is thinner than the headline HeFH statistics suggest. Treating clinicians who prescribe off-label in this setting should document the genetic finding and the rationale, and should not assume the on-label HeFH response rate applies exactly.

What do guideline bodies recommend?

Major guideline groups, including the American College of Cardiology / American Heart Association's cholesterol management guideline, the European Atherosclerosis Society's FH consensus statements, and endocrinology society dyslipidemia guidance, converge on a similar structure: PCSK9 inhibitors including evolocumab are recommended as add-on therapy in FH patients who remain above LDL-C goals despite maximally tolerated statin plus ezetimibe, with earlier or more aggressive use favored in HoFH given the severity of baseline LDL-C burden. This summary paraphrases that consensus rather than reproducing exact guideline wording, since exact quoted guideline language should be verified against the current published guideline text before being presented as a direct quotation.

Practical prescribing and monitoring notes

Evolocumab requires refrigerated storage and is typically allowed to reach room temperature before injection, per the manufacturer's instructions in the FDA label. It is self-administered in the abdomen, thigh, or upper arm, with site rotation to reduce local reactions. There is no routine FDA-required organ-function lab monitoring; LDL-C is generally rechecked some weeks after starting or changing dose to confirm response, with the exact interval a matter of clinical judgment rather than a fixed rule. Evolocumab has no known cytochrome P450 drug interaction because it is cleared as an antibody protein rather than metabolized hepatically, and it is commonly combined with statins and ezetimibe as background therapy. Combining evolocumab with lomitapide or with lipoprotein apheresis in HoFH is done in some specialty centers but is not a formally studied, labeled combination regimen, and should be treated as individualized specialist care rather than a standard protocol.

Safety considerations relevant to FH patients

The most common adverse effects reported across the evolocumab trial program are injection site reactions and nasopharyngitis, each affecting a minority of patients. A dedicated cognitive-safety substudy of FOURIER participants did not find a difference in cognitive function measures between evolocumab and placebo over extended follow-up, which addressed an early theoretical concern about very low LDL-C and neurocognitive risk. Evolocumab has not shown a clear increase in new-onset diabetes risk in trial data, unlike the class warning that applies to statins, though instructions for individualized glucose monitoring should still follow the treating clinician's judgment. No adequate controlled studies exist in pregnancy; IgG antibodies cross the placenta, especially later in pregnancy, and clinicians managing HoFH in patients who may become pregnant should discuss this uncertainty and consider alternatives such as apheresis during pregnancy. None of this substitutes for individualized dosing or diagnostic advice from the prescribing clinician.

What is established, what is plausible, and what is not established

Established: Evolocumab lowers LDL-C substantially in HeFH and to a lesser degree in HoFH, on top of statin therapy, based on multiple randomized controlled trials; it carries an explicit FDA-approved FH indication including a pediatric extension to age 10 and older; major cardiology and lipid guideline bodies recommend PCSK9 inhibitors as add-on therapy in FH patients not at goal on statin plus ezetimibe.

Plausible but not proven by dedicated FH trials: That evolocumab reduces hard cardiovascular events specifically in FH patients (inferred from a general atherosclerotic cardiovascular disease outcomes trial with a small, underpowered FH subgroup, not a dedicated FH outcomes trial); that response rates in APOB-driven or PCSK9-variant FH match LDLR-driven HeFH response rates.

Not established: Long-term safety and effective dosing in children younger than 10; the benefit of formally combining evolocumab with apheresis or lomitapide as a structured regimen beyond individual case reports; head-to-head cardiovascular outcome superiority over alirocumab specifically within an FH population, since no dedicated head-to-head FH outcomes trial exists.

Alternatives and where evolocumab fits among them

Alirocumab (Praluent) is the other approved PCSK9 antibody and carries a comparable HeFH indication but does not currently carry an FDA-approved HoFH indication, which makes evolocumab the default PCSK9 antibody choice specifically for HoFH. Inclisiran (Leqvio), a small interfering RNA targeting PCSK9 messenger RNA, is dosed roughly twice yearly after initiation and has trial data in HeFH showing meaningful LDL-C lowering, but it does not yet have a dedicated cardiovascular outcomes trial in FH and may suit patients for whom adherence to more frequent injections is a barrier. Lipoprotein apheresis, ezetimibe, bempedoic acid, and in HoFH lomitapide remain relevant comparators or adjuncts depending on genotype, LDL-C severity, and patient tolerance, and the choice among them is a specialist-level decision that depends on details this summary cannot substitute for.

FH decision framework: matching the scenario to the evidence base

Use this as a starting orientation for a clinical conversation, not as a treatment protocol. It maps common FH scenarios to FDA status, the strength of the supporting evidence, and the practical next step a clinician or care team typically needs to take.

Access and coverage

Coverage for evolocumab in FH generally requires documentation of a clinical FH diagnosis, elevated baseline LDL-C, and a prior trial of maximally tolerated statin therapy (often with ezetimibe) before approval, and prior authorization is close to universal among commercial and Medicare Part D plans. Off-label prescriptions, such as for a child under 10, face materially higher denial rates and typically need genetic testing documentation and specialist attestation to succeed on appeal. Coverage rules, formulary tiers, and manufacturer patient-assistance program terms change over time and by plan; readers should confirm current terms directly with the payer and with Amgen's patient support resources rather than relying on this summary for current pricing or eligibility rules.